期刊
JOURNAL OF SUBSTANCE ABUSE TREATMENT
卷 132, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jsat.2021.108645
关键词
Opioid use disorders (OUD); Medications for opioid use disorders (MOUD); Health insurance
Patients purchasing retail MOUD prescriptions spent 3.4 times more out-of-pocket on average compared to the rest of the U.S. population, with nearly one-fifth of this population entirely self-paying for their prescriptions. Insurance coverage was associated with significantly reduced annual out-of-pocket MOUD expenditures.
Introduction: High out-of-pocket spending has been a barrier to treatment for the estimated 2.0 million Americans suffering from opioid use disorders (OUD). This paper provides national estimates of financial costs faced by the population receiving retail medications for OUD (MOUD). Methods: We used pooled annual data from the 2011-2017 Medical Expenditure Panel Survey (MEPS), a nationally representative sample of the civilian noninstitutionalized population in the United States. The sample includes individuals who reported filling a retail prescription for buprenorphine or naltrexone, the two most common medications available from retail pharmacies to treat OUD. The main outcome is out-of-pocket spending of retail MOUD prescriptions per fill and per person. Results: Patients with retail MOUD prescriptions spent 3.4 times more out-of-pocket for prescriptions on average than the rest of the U.S. population, with 18.8% of this population paying entirely out-of-pocket for their MOUD prescriptions. Insurance coverage is associated with reduced annual out-of-pocket MOUD expenditures between $316 and $328 per year. Conclusions: Future policies that expand insurance and address out-of-pocket spending on MOUD could increase access to medications among individuals with OUD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据